The epidemics of obesity and chronic diseases in the United States have intensified since the 1960s, surpassing rates in Japan and Europe. This review verifies a U.S. Department of Health and Human Services (HHS) spokesman’s assertion that U.S. obesity is approximately 10 times Japan’s and twice Europe’s, using data from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Organisation for Economic Co-operation and Development (OECD). Historical patterns and regional disparities highlight Vitamin D3 (cholecalciferol) deficiency—worsened by sun avoidance and sunscreen adoption since the 1980s—as the primary driver, especially in diverse U.S. populations with darker skin tones requiring prolonged sun exposure for D3 synthesis. Processed junk foods serve as a secondary factor, often a consequence of D3-induced metabolic cravings and hibernation-like fat storage. RFK Jr.’s focus on diet, while valid, misattributes causality and overlooks D3’s foundational role. Serum 25(OH)D comparisons across regions and U.S. racial groups reveal significant gaps, bolstering D3’s centrality. High-dose D3 protocols, like the Coimbra method, show curative promise for autoimmune diseases, eclipsing dietary interventions. These insights demand a paradigm shift: prioritize D3 restoration to combat obesity and chronic disease epidemics.
Abstract
Horvath’s epigenetic clock research has spotlighted a core set of 48 aging-related genes whose DNA methylation shifts closely track chronological age. These genes – including key transcription factors, splicing regulators, and developmental genes – play pivotal roles in regulating metabolism, maintaining epigenetic patterns, and preserving cellular identity. A unifying theme emerging from this work is the tight interplay between metabolic changes and epigenetic modifications during aging. For instance, older cells exhibit an imbalance in neurotransmitter metabolism: inhibitory GABA levels decline while excitatory glutamate accumulates, contributing to cellular stress and “dedifferentiation” of cell fate control. At the same time, levels of α-ketoglutarate (αKG) – a crucial TCA-cycle metabolite required for DNA demethylation – become depleted with age (due to waning metabolic flux and GABA depletion), impairing the αKG-dependent demethylation of DNA and leading to aberrant hypermethylation and silencing of protective “youth” genes. Compounding this metabolic-epigenetic shift, certain enzymes grow dysregulated with age: monoamine oxidase-B (MAO-B), a FAD-dependent enzyme, is upregulated in aging tissues and sequesters its FAD cofactor, while the NAD⁺-consuming enzyme CD38 is often overactivated, relentlessly hydrolyzing NAD⁺ The combined effect is a drain of two essential mitochondrial cofactors – NAD⁺ and FAD – which starves mitochondria of energy substrates and hampers key repair enzymes, thereby exacerbating cellular aging and dysfunction.Emerging evidence suggests that aging may be driven by such self-reinforcing metabolic and epigenetic disturbances, rather than by a one-way accumulation of random damage. In this view, a decline in metabolites like αKG and NAD⁺ triggers epigenetic dysregulation, which in turn further impairs metabolism, creating a vicious cycle or feedback loop that propels aging forward. This perspective also highlights promising therapeutic interventions aimed at breaking the loop. For instance, restoring αKG levels (through supplementation) could rejuvenate DNA demethylation activity and prevent the silencing of youthful genes, while boosting NAD⁺ (via precursors or CD38 inhibitors) helps sustain sirtuin enzymes and mitochondrial function. Likewise, inhibiting MAO-B could conserve FAD and mitigate oxidative byproducts, especially in the brain, thereby protecting mitochondrial efficiency. By targeting multiple nodes of this network, such interventions – alone or in combination – aim to restore metabolic and epigenetic homeostasis in aged cells Taken together, these findings paint a picture of aging as an actively regulated biological program orchestrated by intertwined metabolic, epigenetic, and mitochondrial dysfunctions.Rather than a passive wear-and-tear process, aging appears to be driven by a dynamic, maladaptive program – one that scientists may increasingly be able to modulate or even reset with multi-pronged therapies.
This framework generates multiple testable predictions and identifies LINE-1 silencing as a unified therapeutic target for multi-system aging intervention.
Keywords: LINE-1, retrotransposon, aging, epigenetic clock, Horvath, Yamanaka factors, programmed aging, heterochromatin, SIRT6, progeria, senescence, comparative aging
How deeply rooted are the molecular drivers of aging, and what does their conservation across plants and animals reveal about longevity itself? Building on Horvath’s landmark epigenetic clock findings (Nature, August 2023), this comparative genomic study probes 49 pivotal genes in mammals, fish, reptiles, birds, insects, plants, bacteria, and archaea. Strikingly, only four of these genes—LARP1, SNX1, HDAC2, and PRC2—emerge as universal eukaryotic anchors, linking epigenetic and developmental processes from leaves to limbs. Beyond these plant-present regulators, additional tiers of conservation appear in insects—yet vanish in simpler prokaryotes—revealing a layered evolutionary tapestry of increasing regulatory sophistication. This cross-kingdom perspective offers potent insights for aging researchers and evolutionary biologists alike, suggesting that the very architecture of longevity is inscribed into genes that first took shape at life’s eukaryotic dawn.
Abstract
Recent anecdotal evidence and clinical observations suggest that high-dose vitamin D3 (cholecalciferol) supplementation may have an underappreciated anti-cancer effect. Concurrently, the metabolic theory of cancer, espoused by Thomas Seyfried and others, highlights the importance of mitochondrial bioenergetics and the Warburg effect in oncogenesis. This article synthesizes these perspectives, proposing that high-dose vitamin D3 can enhance mitochondrial function and provide the energetic “push” needed to carry out proper apoptosis—a process that can stall under conditions of metabolic insufficiency. We further explore how classic oncogenic mutations (e.g., TP53, RB1, PTEN, BCL-2 family genes) compromise apoptosis in ways that are exacerbated by impaired mitochondrial energy output. Drawing from case reports, mechanistic studies on vitamin D3 and histone deacetylases (particularly HDAC2), and the evolutionary logic that cancer may be a reversion to a more primordial cell state, we present a compelling case for high-dose vitamin D3 as an adjunctive or primary therapy that targets the metabolic underpinnings of malignancies.
This multimodal model reveals Alzheimer’s disease not as a single pathological process, but as the inevitable consequence of evolutionarily-programmed aging systems that co-opt each other’s vulnerabilities 145. The evidence suggests that:
Aging is programmed: The precise coordination of these declining systems suggests evolutionary selection for aging rather than random deterioration 128
RNA-level intervention is key: Since the damage occurs at the mRNA splicing level rather than DNA, aging remains potentially reversible 12526
Early intervention is critical: The cascade accelerates once multiple systems are compromised, making prevention far more effective than late-stage treatment 45
Combination therapy is essential: No single intervention can address the interconnected nature of this multi-system failure 145
This paradigm shift from viewing Alzheimer’s as an isolated brain disease to understanding it as the culmination of coordinated aging systems opens new therapeutic possibilities and explains why previous single-target approaches have largely failed. The future of Alzheimer’s treatment lies in addressing this complex, interconnected cascade at multiple levels simultaneously.